Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Shaq is not Alone: Free-Throws in the Final Moments of a Basketball Game.

Gómez MÁ, Avugos S, Oñoro MÁ, Lorenzo A, Bar-Eli M.

J Hum Kinet. 2018 Jun 13;62:135-144. doi: 10.1515/hukin-2017-0165. eCollection 2018 Jun.

2.

ADAR1-mediated regulation of melanoma invasion.

Nemlich Y, Baruch EN, Besser MJ, Shoshan E, Bar-Eli M, Anafi L, Barshack I, Schachter J, Ortenberg R, Markel G.

Nat Commun. 2018 May 31;9(1):2154. doi: 10.1038/s41467-018-04600-2.

3.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 May 29. pii: 122301. doi: 10.1172/JCI122301. [Epub ahead of print] No abstract available.

4.

A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.

Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood A, Bar-Eli M.

Nat Commun. 2018 Jan 31;9(1):461. doi: 10.1038/s41467-018-02851-7.

5.

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK.

Clin Cancer Res. 2017 Nov 15;23(22):7034-7046. doi: 10.1158/1078-0432.CCR-17-0647. Epub 2017 Aug 29.

PMID:
28855350
6.

N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration.

Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA.

Genome Biol. 2017 May 24;18(1):98. doi: 10.1186/s13059-017-1224-0.

7.

Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.

Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, Huang L, Shoshan E, Velazquez-Torres G, Nitti G, Lee S, Lee JG, Fuentes-Mattei E, Willis D, Zhang L, Guo CC, Yao H, Baggerly K, Lotan Y, Lerner SP, Dinney C, McConkey D, Bar-Eli M, Czerniak B.

Sci Rep. 2017 Jan 19;7:40714. doi: 10.1038/srep40714.

8.

Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis.

Jinesh GG, Molina JR, Huang L, Laing NM, Mills GB, Bar-Eli M, Kamat AM.

Cell Death Discov. 2016 Feb 1;2:16003. doi: 10.1038/cddiscovery.2016.3. eCollection 2016.

9.

Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection.

Rosero RA, Villares GJ, Bar-Eli M.

Front Genet. 2016 Jun 15;7:112. doi: 10.3389/fgene.2016.00112. eCollection 2016. Review.

10.

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.

Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK.

Nat Commun. 2016 Apr 4;7:11169. doi: 10.1038/ncomms11169.

11.

NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis.

Shoshan E, Braeuer RR, Kamiya T, Mobley AK, Huang L, Vasquez ME, Velazquez-Torres G, Chakravarti N, Ivan C, Prieto V, Villares GJ, Bar-Eli M.

Cancer Res. 2016 Jun 1;76(11):3145-55. doi: 10.1158/0008-5472.CAN-15-2511. Epub 2016 Mar 24.

12.

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.

Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK.

Oncogene. 2016 Aug 18;35(33):4312-20. doi: 10.1038/onc.2015.492. Epub 2016 Jan 4.

13.

Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.

Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE.

Clin Cancer Res. 2016 Jan 1;22(1):107-21. doi: 10.1158/1078-0432.CCR-15-0235. Epub 2015 Aug 13.

14.

Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.

Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A, Langut Y, Bar-Eli M, Reuveni H, Levitzki A.

Oncogene. 2016 May 19;35(20):2675-80. doi: 10.1038/onc.2015.229. Epub 2015 Jun 29.

PMID:
26119932
15.

Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.

Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli M.

Nat Cell Biol. 2015 Mar;17(3):311-21. doi: 10.1038/ncb3110. Epub 2015 Feb 16.

16.

How should "hot" players in basketball be defended? The use of fast-and-frugal heuristics by basketball coaches and players in response to streakiness.

Csapo P, Avugos S, Raab M, Bar-Eli M.

J Sports Sci. 2015;33(15):1580-8. doi: 10.1080/02640414.2014.999251. Epub 2015 Jan 8.

PMID:
25567138
17.

The effect of perceived streakiness on the shot-taking behaviour of basketball players.

Csapo P, Avugos S, Raab M, Bar-Eli M.

Eur J Sport Sci. 2015;15(7):647-54. doi: 10.1080/17461391.2014.982205. Epub 2014 Nov 27.

PMID:
25427817
18.

Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.

Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK.

Nat Commun. 2014 Oct 29;5:5202. doi: 10.1038/ncomms6202.

19.

The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis.

Izraely S, Sagi-Assif O, Klein A, Meshel T, Ben-Menachem S, Zaritsky A, Ehrlich M, Prieto VG, Bar-Eli M, Pirker C, Berger W, Nahmias C, Couraud PO, Hoon DS, Witz IP.

Int J Cancer. 2015 Mar 15;136(6):1296-307. doi: 10.1002/ijc.29090. Epub 2014 Sep 8.

20.

Monocyte subpopulations in angiogenesis.

Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK.

Cancer Res. 2014 Mar 1;74(5):1287-93. doi: 10.1158/0008-5472.CAN-13-2825. Epub 2014 Feb 20. Review.

21.

Why is melanoma so metastatic?

Braeuer RR, Watson IR, Wu CJ, Mobley AK, Kamiya T, Shoshan E, Bar-Eli M.

Pigment Cell Melanoma Res. 2014 Jan;27(1):19-36. doi: 10.1111/pcmr.12172. Epub 2013 Oct 17. Review.

PMID:
24106873
22.

Crossing the junction in the gap of melanoma brain metastasis.

Kamiya T, Mobley AK, Bar-Eli M.

Pigment Cell Melanoma Res. 2013 Jul;26(4):435-7. doi: 10.1111/pcmr.12095. Epub 2013 Apr 4. No abstract available.

PMID:
23923820
23.

MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.

Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G.

J Clin Invest. 2013 Jun;123(6):2703-18.

24.

Therapeutic destruction of insulin receptor substrates for cancer treatment.

Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, Levitzki A.

Cancer Res. 2013 Jul 15;73(14):4383-94. doi: 10.1158/0008-5472.CAN-12-3385. Epub 2013 May 7.

25.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.

26.

Src activation by β-adrenoreceptors is a key switch for tumour metastasis.

Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK.

Nat Commun. 2013;4:1403. doi: 10.1038/ncomms2413. Erratum in: Nat Commun. 2013;4:1932. Shazhad, Mian M K [corrected to Shahzad, Mian M K].

27.

Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin.

Braeuer RR, Zigler M, Kamiya T, Dobroff AS, Huang L, Choi W, McConkey DJ, Shoshan E, Mobley AK, Song R, Raz A, Bar-Eli M.

Cancer Res. 2012 Nov 15;72(22):5757-66. doi: 10.1158/0008-5472.CAN-12-2424. Epub 2012 Sep 17.

28.

Driving transcriptional regulators in melanoma metastasis.

Mobley AK, Braeuer RR, Kamiya T, Shoshan E, Bar-Eli M.

Cancer Metastasis Rev. 2012 Dec;31(3-4):621-32. doi: 10.1007/s10555-012-9358-8. Review.

PMID:
22684365
29.

The sweet and bitter sides of galectins in melanoma progression.

Braeuer RR, Shoshan E, Kamiya T, Bar-Eli M.

Pigment Cell Melanoma Res. 2012 Sep;25(5):592-601. doi: 10.1111/j.1755-148X.2012.01026.x. Epub 2012 Jul 12. Review.

PMID:
22672152
30.
31.

Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells.

Mu H, Calderone TL, Davies MA, Prieto VG, Wang H, Mills GB, Bar-Eli M, Gershenwald JE.

Am J Pathol. 2012 May;180(5):2170-81. doi: 10.1016/j.ajpath.2012.03.003. Epub 2012 Mar 30.

32.

PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.

Zigler M, Kamiya T, Brantley EC, Villares GJ, Bar-Eli M.

Cancer Res. 2011 Nov 1;71(21):6561-6. doi: 10.1158/0008-5472.CAN-11-1432. Epub 2011 Oct 18. Review.

33.

A phase II study of gefitinib in patients with metastatic melanoma.

Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY.

Melanoma Res. 2011 Aug;21(4):357-63. doi: 10.1097/CMR.0b013e3283471073.

34.

Searching for the 'melano-miRs': miR-214 drives melanoma metastasis.

Bar-Eli M.

EMBO J. 2011 May 18;30(10):1880-1. doi: 10.1038/emboj.2011.132. Review. No abstract available.

35.

Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression.

Zigler M, Villares GJ, Dobroff AS, Wang H, Huang L, Braeuer RR, Kamiya T, Melnikova VO, Song R, Friedman R, Alani RM, Bar-Eli M.

Cancer Res. 2011 May 15;71(10):3494-504. doi: 10.1158/0008-5472.CAN-10-3555. Epub 2011 Apr 5.

36.

The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.

Villares GJ, Zigler M, Bar-Eli M.

Oncotarget. 2011 Jan-Feb;2(1-2):8-17. Review.

37.

Chitosan hydrogel for localized gene silencing.

Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G, Sood AK.

Cancer Biol Ther. 2011 May 1;11(9):839-45. Epub 2011 May 1.

38.

Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.

Villares GJ, Zigler M, Dobroff AS, Wang H, Song R, Melnikova VO, Huang L, Braeuer RR, Bar-Eli M.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):626-31. doi: 10.1073/pnas.1006886108. Epub 2010 Dec 27.

39.

Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.

Black PC, Brown GA, Dinney CP, Kassouf W, Inamoto T, Arora A, Gallagher D, Munsell MF, Bar-Eli M, McConkey DJ, Adam L.

J Urol. 2011 Feb;185(2):693-700. doi: 10.1016/j.juro.2010.09.082. Epub 2010 Dec 18.

PMID:
21168861
40.

Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment.

Braeuer RR, Zigler M, Villares GJ, Dobroff AS, Bar-Eli M.

Semin Cancer Biol. 2011 Apr;21(2):83-8. doi: 10.1016/j.semcancer.2010.12.007. Epub 2010 Dec 13. Review.

41.

Estela Medrano, 1943-2010.

Abdel-Malek Z, Bar-Eli M.

Pigment Cell Melanoma Res. 2010 Dec;23(6):724. doi: 10.1111/j.1755-148X.2010.00776.x. No abstract available.

PMID:
20973929
42.

Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.

Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK.

J Biol Chem. 2010 Nov 12;285(46):35462-70. doi: 10.1074/jbc.M110.109579. Epub 2010 Sep 8.

43.

Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels.

Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, Bar-Eli M, Aldape KD, Fidler IJ.

Neoplasia. 2010 Sep;12(9):748-54.

44.

CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.

Melnikova VO, Dobroff AS, Zigler M, Villares GJ, Braeuer RR, Wang H, Huang L, Bar-Eli M.

PLoS One. 2010 Aug 27;5(8):e12452. doi: 10.1371/journal.pone.0012452.

45.

Cell adhesion: implication in tumor progression.

Zigler M, Dobroff AS, Bar-Eli M.

Minerva Med. 2010 Jun;101(3):149-62. Review.

PMID:
20562803
46.

The dicey role of Dicer: implications for RNAi therapy.

Merritt WM, Bar-Eli M, Sood AK.

Cancer Res. 2010 Apr 1;70(7):2571-4. doi: 10.1158/0008-5472.CAN-09-2536. Epub 2010 Feb 23. Review.

47.

Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.

Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, McCarthy JB.

Cancer Res. 2009 Oct 1;69(19):7538-47. doi: 10.1158/0008-5472.CAN-08-4626. Epub 2009 Sep 8.

48.

Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis.

Melnikova VO, Balasubramanian K, Villares GJ, Dobroff AS, Zigler M, Wang H, Petersson F, Price JE, Schroit A, Prieto VG, Hung MC, Bar-Eli M.

J Biol Chem. 2009 Oct 16;284(42):28845-55. doi: 10.1074/jbc.M109.042150. Epub 2009 Aug 24.

49.

Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43.

Villares GJ, Dobroff AS, Wang H, Zigler M, Melnikova VO, Huang L, Bar-Eli M.

Cancer Res. 2009 Aug 15;69(16):6730-7. doi: 10.1158/0008-5472.CAN-09-0300.

50.

miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.

Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C.

Clin Cancer Res. 2009 Aug 15;15(16):5060-72. doi: 10.1158/1078-0432.CCR-08-2245. Epub 2009 Aug 11.

Supplemental Content

Loading ...
Support Center